Brownsburg

This trial evaluates the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. The study focuses on reducing uric acid to below 6.0 mgdL after 24 weeks of treatment, addressing a common complication in gout patients. It is a phase 3, randomized, double-blind study involving adult participants aged 18 to 75 years with a history of gout. Participants are randomly assigned to one of three groups one group continues allopurinol at their existing dose once daily through week 64 the second group receives dotinurad starting at 1 mg once daily for the first 4 weeks, then 2 mg once daily through week 64 the third group begins with 1 mg daily for 4 weeks, increases to 2 mg daily for 8 weeks, then continues 4 mg daily through week 64. All treatments are administered orally as over-encapsulated tablets. Throughout the study, participants undergo regular monitoring of serum uric acid levels and gout flares from baseline up to week 68. Assessments include measuring the percentage of participants achieving target uric acid levels at various points, gout flare rates, and treatment-emergent adverse events. The study also evaluates safety and tolerability over the course of the treatment period, which lasts up to approximately 68 weeks including follow-up.

Researchers are evaluating LY3457263 compared with a placebo in adults with type 2 diabetes who have not reached their hemoglobin A1c HbA1c goal despite being on stable doses of semaglutide or tirzepatide. This Phase 2, double-blind study focuses on measuring changes in HbA1c levels. Participation in the trial lasts about nine months, aiming to provide insights into treatment effects in this specific patient group. Participants will be randomly assigned to receive one of three doses of LY3457263 or a placebo, all given by subcutaneous injection once weekly. The study uses a parallel-group design where each participant receives only one assigned treatment. The trial compares these treatments over a 24-week period to assess their impact on blood sugar control and body weight. During the study, participants will undergo regular assessments including blood tests to measure HbA1c and fasting serum glucose, as well as body weight measurements. These evaluations occur at baseline and at 24 weeks. The study team will monitor participants health and treatment effects throughout the trial, which is expected to last about nine months in total.

Researchers are evaluating the safety and effectiveness of solbinsiran compared to a placebo in adults with severe hypertriglyceridemia, a condition involving very high triglyceride levels. This Phase 2, randomized, double-blind, placebo-controlled study aims to understand how solbinsiran affects triglycerides and other lipid measures. The study focuses on participants with fasting triglyceride levels of 500 mgdL or higher. Participants will be randomly assigned to receive either solbinsiran or a placebo through two subcutaneous injections. The study uses a parallel design, meaning participants receive only one of the two treatments. The trial will last at least 24 weeks, with assessments occurring from baseline through weeks 16 to 24 to measure changes in triglycerides and other lipids. During the study, participants will undergo evaluations of lipid levels including triglycerides, Angiopoietin-like-3, very-low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol. Pharmacokinetic assessments will be done to measure the drug concentration over time. Safety and efficacy will be monitored throughout the trial, which is expected to complete in August 2027.